Lung Therapeutics Selects QbDVision for CMC Agility

Today we are excited to announce that Lung Therapeutics has selected to implement QbDVision to provide critical transparency between R&D, process development, manufacturing, and commercialization.

We’ve had the privilege of working with the Lung Therapeutics team to pilot QbDVision as the system of record for CMC data. Their forward-thinking approach and commitment to get it “right the first time” makes them a great partner to work with.

During the pilot process, we’ve gotten to know the team and understand their critical mission of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments.

“We believe QbDVision is the right partner to support our product development and through this relationship, we will be able to achieve the high standards to which we aspire,” said Matt Karpen, Director of CMC, about the selection.

{{lung-therapeutics-cmc-agility-q1}}

Lung Therapeutics can effectively structure, link, and track multiple dimensions of information driving process understanding and simplifying tech transfer throughout the development lifecycle.

We built QbDVision to allow companies like Lung Therapeutics to operate with a vision for the highest quality product in mind. Our digital solution enables process agility and a level of process understanding never before possible. As their processes evolve over time and the move towards commercial manufacturing, we’ll be there to support and partner with them.